<DOC>
	<DOCNO>NCT01644968</DOCNO>
	<brief_summary>This study design determine safety high tolerate dose anti-OX40 patient advanced cancer .</brief_summary>
	<brief_title>Phase 1 Study Anti-OX40 Patients With Advanced Cancer</brief_title>
	<detailed_description>This study evaluate safety determine maximal tolerate dose anti-OX40 ; evaluate immune response study treatment ; measure pharmacokinetics anti-OX40 ; monitor tumor regression , identify biologically active dose anti-OX40 induce antigen-specific response variety immunogen .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients uncurable metastatic carcinoma , lymphoma , sarcoma . ECOG performance status 0 , 1 , 2 No active bleeding No clinical coagulopathy Anticipated lifespan great 12 week Active residual toxicity prior therapy Active Infection HIV positive Hepatitis B C positive Pregnant nursing woman Requirement oral steroid Brain metastasis Presence history autoimmune disease Shellfish tetanus allergy Splenomegaly Lymph nod great 10 cm maximal diameter Uncontrolled angina class II IV heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>metastatic carcinoma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>sarcoma</keyword>
	<keyword>anti-OX40</keyword>
</DOC>